New hope for rare nerve disease: early trial of NouvSoma001 begins

NCT ID NCT06620809

First seen Feb 01, 2026 · Last updated Apr 28, 2026 · Updated 11 times

Summary

This early-stage trial tests a new treatment called NouvSoma001 for people with neuromyelitis optica spectrum disorder (NMOSD), a rare disease that attacks the nerves in the eyes and spinal cord. The treatment uses tiny particles from stem cells, injected into the spine, to try to calm the immune attack. The main goal is to check if it is safe and tolerable, with a small number of participants receiving either the treatment or a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.